A5069315060- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- CAR-T cell therapy research
- Histone Deacetylase Inhibitors Research
- Gut microbiota and health
- HIV/AIDS drug development and treatment
- Drug Transport and Resistance Mechanisms
- Acute Lymphoblastic Leukemia research
- Chemotherapy-related skin toxicity
- Clostridium difficile and Clostridium perfringens research
- Ubiquitin and proteasome pathways
- Central Venous Catheters and Hemodialysis
- Dermatology and Skin Diseases
- Integrated Circuits and Semiconductor Failure Analysis
- Oral and gingival health research
- Cancer Genomics and Diagnostics
- Renal Transplantation Outcomes and Treatments
- Cancer therapeutics and mechanisms
- Parasites and Host Interactions
- Silicon Carbide Semiconductor Technologies
Hackensack University Medical Center
2014-2024
Hackensack Meridian Health
2018-2024
Here, we report on a phase IIa study to determine the intubation rate, survival, viral clearance, and development of endogenous Abs in patients with COVID-19 pneumonia treated convalescent plasma (CCP) containing high levels neutralizing anti-SARS-CoV-2 Abs. Radiographic laboratory evaluation confirmed all 51 had pneumonia. Fresh or frozen CCP from donors titers was administered. The nonmechanically ventilated (n = 36) an rate 13.9% 30-day survival 88.9%, overall for comparative group based...
Not available.
Fludarabine, cyclophosphamide, and rituximab (FCR) remains the standard of care for fit chronic lymphocytic leukemia (CLL) patients requiring first therapy. However, side effects can be significant, with poor risk features have inferior outcomes. The purpose this study was to evaluate reduced‐dose FCR (FCR‐Lite) plus lenalidomide (FCR 2 ) followed by maintenance as a strategy shorten immunochemotherapy in untreated CLL. Patients received four six cycles . who were minimal residual disease...
ABSTRACT OBJECTIVES To determine the rate of intubation, overall survival, viral clearance, and development endogenous antibodies in patients with COVID-19 pneumonia treated convalescent plasma containing high levels neutralizing anti-SARS-CoV-2 antibodies. We also aimed to describe laboratory parameters products. DESIGN This was a phase IIa, single institution, prospective study adults hospitalized SARS-CoV-2 pneumonia. SETTING Hackensack University Medical Center, 770-bed research teaching...
Autologous hematopoietic stem cell transplantation (ASCT) is a standard-of-care treatment for many hematologic malignancies. Progression of disease after ASCT the primary cause failure. In this Phase Ib trial, we studied safety and clinical effect combined checkpoint inhibition therapy (CPIT) with ipilimumab nivolumab as consolidation strategy patients high-risk diffuse large B lymphoma (DLBCL), mature T (TCL), multiple myeloma (MM). Starting at 14 to 28 days ASCT, received (1 mg/kg i.v. on...
e20043 Background: Iberdomide is a next generation cereblon-E3 ligase modulating agent (CELMoD) that has increased antitumor activity relative to earlier thalidomide analogs (IMiDs). This due direct effects on tumor cells and immune surveillance. Herein, we report the dose escalation, safety efficacy data from this ongoing study of carfilzomib (CFZ), iberdomide, dexamethasone (DEX) (KID) in patients with newly diagnosed transplant-eligible multiple myeloma (MM). Methods: phase I/II,...
The global SARS-CoV-2 coronavirus pandemic continues to be devastating in many areas. Treatment options have been limited and convalescent donor plasma has used by centers transfer passive neutralizing antibodies patients with respiratory involvement. results often vary institution are complicated the nature quality of itself, timing administration clinical aspects recipients. infection is known associated an increase blood concentrations several inflammatory cytokines/chemokines, as part...
Patients with high-risk multiple-myeloma (HRMM) and ultra-high-risk (UHRMM) show rapid disease progression shorter survival compared to those standard-risk (SRMM). Lenalidomide maintenance after autologous stem cell transplant (ASCT) has shown inferior outcomes in this subgroup SRMM, there is an unmet need for improved post-ASCT therapy. This retrospective study, from September 2016 March 2023, assesses elotuzumab combined lenalidomide or pomalidomide dexamethasone (ERd EPd) as consolidation...
Background and purpose The aim of this study was to determine the prevalence patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease encompassable in a standard radiation (RT) plan (defined as <5 malignant lesions) may benefit from bridging RT prior CART. Materials methods This is single-center, retrospective R/R NHL received CART 2018 2022. Eligible had pre-apheresis...
Mantle cell lymphoma (MCL) is a rare non-Hodgkin that frequently becomes chemoresistant over time. The distinct mechanisms of ibrutinib and lenalidomide provided judicious rationale to explore the combination with anti-CD20 immunotherapy. In this phase 1b study (NCT02446236), patients (n = 25) relapsed/refractory MCL received rituximab escalating doses (days 1–21) 560 mg 1–28) 28-day cycles. MTD for was 20 mg; most common grade ≥3 adverse events were skin rashes (32%) neutropenic fever...
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin (NHL) and carries a great deal diversity. Although nearly 60% patients can be cured with standard rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, 35% relapse (80% within 1st 18 mo), 10%–15% reveal primary refractory DLBCL. While typical salvage high-dose therapy followed by autologous stem cell transplantation (HDT-ASCT), early failure chemoimmunotherapy do very poorly as shown in SCHOLAR-1...
e20042 Background: Selinexor is an oral, selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1), leading to retention tumor suppressor proteins and apoptosis in malignant cells. Preclinical studies suggest synergistic activity when selinexor combined with other treatments for MM. We hypothesize the addition can recapture response patients relapsing or refractory on carfilzomib (CFZ), pomalidomide (POM) daratumumab (DARA)-based regimens. Methods: This ongoing phase IIb,...